We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,999

Amgen Inc. v. Apotex Inc
  • Winston & Strawn LLP
  • USA
  • August 29 2016

Amgen Inc. brought an action against Apotex Inc. under the Biologics Price Competition and Innovation Act (BPCIA) alleging that Apotex’s marketing of


California High Court Expands “Specific” Personal Jurisdiction To Recreate Exorbitant” Personal Jurisdiction Rejected by Daimler v. Bauman
  • Reed Smith LLP
  • USA
  • August 29 2016

It’s been two years since the First District California Court of Appeals issued its ill-founded decision in Bristol-Myers Squibb Co. v. Superior Court


ASA Adjudications Snapshot - July 2016
  • CMS
  • United Kingdom
  • August 26 2016

This summary provides a selection of July’s most interesting ASA adjudications and highlights the key issues considered in those adjudications. This


Childhood obesity, the Sugar Tax & advertising to children - The Latest
  • CMS
  • United Kingdom
  • August 19 2016

The government has now published its long-awaited Childhood Obesity report. The report itself was relatively short (a mere 8 pages of content


Update: More on Marijuana Advertising
  • Wilkinson Barker Knauer LLP
  • USA
  • August 19 2016

In the few days since I posted this update on concerns about marijuana advertising, there has been much attention devoted to the subject - and none


Branding 101 - Should puffery be avoided in healthcare advertising?
  • Husch Blackwell LLP
  • USA
  • August 18 2016

Healthcare is a highly competitive market. Healthcare companies are hiring marketing teams to lure customers to their facility. This will invariably


FDA Continues to Schedule Marijuana as a Schedule I Drug - Doing Nothing to Clarify the Still Murky State of Broadcast Advertising
  • Wilkinson Barker Knauer LLP
  • USA
  • August 17 2016

Last week's letter from the FDA detailing its position that there should be no change in marijuana being classified as a Schedule I drug under


NAD Recommends Mars Modify CocoaVia Dietary Supplement Claim
  • Winston & Strawn LLP
  • USA
  • August 16 2016

After an National Advertising Division (NAD) inquiry, Mars Incorporated recently agreed to modify or permanently discontinue certain advertising


Political adverts - freedom to misinform?
  • RPC
  • United Kingdom
  • August 15 2016

Promises of an additional £350m per week to be given to the NHS, posters featuring "white thugs" shouting at vulnerable old ladies, and billboards


A Tour of NAD Takes on Claims
  • Kelley Drye & Warren LLP
  • USA
  • August 15 2016

The NAD recently reviewed claims for an omega-3 supplement. See Prevention Pharmaceuticals, Inc., NAD Case No. 5966 (July 2016). The NAD found that